Emergent BioSolutions (EBS) EBT Margin Growth (1y) (2012 - 2026)
Emergent BioSolutions (EBS) EBT Margin Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1,585.00 |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -177.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -27.00 |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -356.00 |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 436.00 |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -629.00 |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 208.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Emergent BioSolutions | 261.35 Mn | 120.45 Mn | 137.20 Mn | -5,905.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5,905.00 |
| Mar 31, 2026 | -3,313.00 |
| Dec 31, 2025 | -1,992.00 |
| Sep 30, 2025 | -2,354.00 |
| Jun 30, 2025 | 52,768.00 |
| Mar 31, 2025 | 3,769.00 |
| Dec 31, 2024 | 553.00 |
| Sep 30, 2024 | 14,677.00 |
| Jun 30, 2024 | -46,555.00 |
| Mar 31, 2024 | 10,178.00 |
| Dec 31, 2023 | -111.00 |
| Sep 30, 2023 | -7,029.00 |
| Jun 30, 2023 | -3,992.00 |
| Mar 31, 2023 | -9,650.00 |
| Dec 31, 2022 | -5,357.00 |
| Sep 30, 2022 | -1,212.00 |
| Jun 30, 2022 | -3,604.00 |
| Mar 31, 2022 | -2,385.00 |
| Dec 31, 2021 | -920.00 |
| Sep 30, 2021 | -3,017.00 |